Ask AI
ProCE Banner Series

Think You Know JAK? Essential Evidence to Aid Your Clinical Implementation of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo

Explore the latest evidence and practical strategies for using JAK inhibitors in atopic dermatitis, alopecia areata, and vitiligo, including how to assess patient candidacy, interpret safety and efficacy data, and develop individualized monitoring plans. This interactive education is designed to help healthcare professionals apply emerging data to improve treatment decision-making and patient communication in dermatology practice.

  AAPA
  | ANCC
Who Should Attend

This activity is intended for nurse practitioners and physician associates who are involved in the management of patients with alopecia areata, atopic dermatitis, and vitiligo.

All Events

Think You Know JAK? Essential Evidence to Aid Your Clinical Implementation of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo

Upcoming Events

September

19

2026

6:30 AM - 7:45 AM Eastern Time (ET)

In-person

The Greenbrier, 101 W Main St, White Sulphur Springs, West Virginia 24986

6:45 AM - 7:45 AM Eastern Time (ET)

Virtual

November

07

2026

5:30 PM - 7:00 PM Central Time (CT)

In-person

Hyatt Regency Lost Pines, 575 Hyatt Lost Pines Rd, Cedar Creek, Texas 78612

6:00 PM - 7:00 PM Central Time (CT)

Virtual

Topics

Atopic dermatitis, Alopecia

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this educational activity is to improve learners’ knowledge and competence in evidence-based use of JAK inhibitor therapies for patients with alopecia areata, atopic dermatitis, and vitiligo.

Target Audience
This activity is intended for nurse practitioners and physician associates who are involved in the management of patients with alopecia areata, atopic dermatitis, and vitiligo.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Incorporate long-term safety and efficacy data for JAK inhibitors into treatment strategies for patients with atopic dermatitis

  • Evaluate recent clinical evidence for current and emerging JAK inhibitors in alopecia areata

  • Identify patients with vitiligo most likely to benefit from JAK inhibitor therapies based on emerging clinical trial evidence

  • Determine the role of JAK-STAT signaling in the pathophysiology of AA, AD, and vitiligo

  • Develop appropriate monitoring plans for patients with AA, AD, and vitiligo receiving JAK inhibitor therapy

  • Educate patients about the potential risks and benefits of JAK inhibitor therapies in AA, AD, and vitiligo

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Smart Patients.  Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (Partners) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation. 

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners' policies.

Acknowledgement

Provided by

Provided by Partners for Advancing Clinical Education (Partners), in partnership with Decera Clinical Education and Smart Patients.

Partners for Advancing Clinical Education (Partners) 2025

Supporters

Supported by an independent educational grant from AbbVie.

AbbVie

Partners

Smart Patients

ProCE Banner

Decera Clinical Education

ProCE Banner

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191